SCHEMBL367105

SCHEMBL367105

C=CC(C)(O)OC(=O)c1ccccc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
ALOX15 P16050 2/20 0.45
CYP3A4 P08684 1/20 0.41
KMT2A Q03164 1/20 0.38
AKR1C3 P42330 2/20 0.38
KDM4E B2RXH2 5/20 0.38
HSD17B10 Q99714 4/20 0.38
HPGD P15428 4/20 0.38
TSHR P16473 2/20 0.38
HMGB1 P09429 2/20 0.38
NAPRT Q6XQN6 2/20 0.38
ESR1 P03372 1/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
GGT1 P19440 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
BLM P54132 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
RIPK1 Q13546 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL867866 0.87 ALDH1A1 (0.48) ALDH1A1ALOX15CYP3A4KMT2AAKR1C3
SCHEMBL10581907 0.83 ALDH1A1 (0.44) ALDH1A1ALOX15CYP3A4KMT2AAKR1C3
SCHEMBL828388 0.81 ALDH1A1 (0.54) ALDH1A1ALOX15AKR1C3KDM4EHSD17B10
SCHEMBL867865 0.81 CYP3A4 (0.47) ALDH1A1ALOX15CYP3A4HSD17B10TSHR
SCHEMBL27710480 0.79 ALDH1A1 (0.44) ALDH1A1ALOX15CYP3A4KMT2AAKR1C3
SCHEMBL28331298 0.79 ALDH1A1 (0.45) ALDH1A1ALOX15CYP3A4KMT2AKDM4E
SCHEMBL30339401 0.79 ALDH1A1 (0.56) ALDH1A1ALOX15AKR1C3KDM4EHSD17B10
SCHEMBL722115 0.79 ALDH1A1 (0.56) ALDH1A1ALOX15AKR1C3KDM4EHSD17B10
SCHEMBL7196758 0.78 ALDH1A1 (0.42) ALDH1A1ALOX15CYP3A4KMT2AAKR1C3
Water SCHEMBL28274877 0.78 ALDH1A1 (0.54) ALDH1A1ALOX15AKR1C3KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542223-B1 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2015-09-23 EP claimed
EP-2542223-A2 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF Hanmi Science Co., Ltd. (KR) 2013-01-09 EP claimed
US-20120321709-A1 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2012-12-20 US claimed
US-20120015032-A1 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME HANALL PHARMACEUTICAL COMPANY, LTD. (KR) 2012-01-19 US claimed
WO-2011108826-A2 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF HANMI HOLDINGS CO., LTD. (KR) 2011-09-09 WO claimed
US-20110123612-A1 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER HANALL BIOPHARMA CO., LTD (KR) 2011-05-26 US claimed
US-20110117194-A1 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER HANALL BIOPHARMA CO., LTD. (KR) 2011-05-19 US claimed
US-20110111022-A1 PHARMACEUTICAL FORMULATION HANALL BIOPHARMA CO., LTD. (KR) 2011-05-12 US claimed
US-20110111021-A1 PHARMACEUTICAL PREPARATION HANALL BIOPHARMA CO., LTD. (KR) 2011-05-12 US claimed
US-20110052683-A1 PHARMACEUTICAL PREPARATION FOR TREATING CARDIOVASCULAR DISEASE HANALL BIOPHARMA CO., LTD. (KR) 2011-03-03 US claimed
US-20110038931-A1 COMPOSITE PREPARATION HANALL BIOPHARMA CO., LTD. (KR) 2011-02-17 US claimed
EP-2281557-A2 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER HanAll Biopharma Co., Ltd. (KR) 2011-02-09 EP claimed
EP-2275093-A2 PHARMACEUTICAL FORMULATION HanAll Biopharma Co., Ltd. (KR) 2011-01-19 EP claimed
EP-2255797-A2 COMPOSITE PREPARATION HanAll Biopharma Co., Ltd. (KR) 2010-12-01 EP claimed
EP-2255796-A2 PHARMACEUTICAL PREPARATION HanAll Biopharma Co., Ltd. (KR) 2010-12-01 EP claimed
EP-2180891-A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME Hanall Pharmaceutical Co., Ltd. (KR) 2010-05-05 EP claimed
WO-2009022821-A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME HANALL PHARMACEUTICAL COMPANY. LTD (KR) 2009-02-19 WO claimed
WO-2023128710-A1 TABLET CONTAINING MIXED EXTRACT OF CINNAMOMI RAMULUS AND MOUTAN RADICIS CORTEX AS ACTIVE INGREDIENT AND COMPOSITION DESIGNED TO ADMINISTER SPECIFIC DOSAGE THEREOF FOR TREATMENT 주식회사 큐라클 2023-07-06 WO disclosed
EP-2180891-A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME Hanall Pharmaceutical Co., Ltd. (KR) 2010-05-05 EP disclosed
WO-2009022821-A2 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME HANALL PHARMACEUTICAL COMPANY. LTD (KR) 2009-02-19 WO disclosed